Evidence map›Paper›PMID 41493718›Full record

Trial reportInternational journal of hematology2026

Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial.

Kazutaka Sunami, Hiroshi Handa, Michiko Ichii, Takayuki Ikezoe, Kazuhito Suzuki, Yusuke Yamaguchi, Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Eric Lewis and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04484623 (A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04484623 phase3active not recruitingnot on this map

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

TypeinterventionalSponsorGlaxoSmithKlineRan2020 to 2029Enrolled302ConditionsMultiple MyelomaArmsBelantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama City, Japan. kazusuna@pop12.odn.ne.jp.
Hiroshi HandaDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.
Michiko IchiiThe University of Osaka Graduate School of Medicine, Osaka, Japan.
Takayuki IkezoeFukushima Medical University, Fukushima, Japan.
Kazuhito SuzukiThe Jikei University School of Medicine, Tokyo, Japan.
Yusuke YamaguchiGSK Tokyo, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan.
Taeko YonekawaGSK Tokyo, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan.
Akira EndoGSK Tokyo, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan.
Hirofumi NakanoGSK Tokyo, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan.
Eric LewisGSK, Durham, NC, USA.
Ianire Garrobo CallejaGSK, London, UK.
Elisabet ManasanchGSK, Philadelphia, PA, USA.
Shigeki ItoDivision of Hematology & Oncology, Iwate Medical University School of Medicine, Iwate, Japan.
Hitomi KatoGSK Tokyo, 1-8-1, Akasaka, Minato-ku, Tokyo, Japan. hitomi.x.kato@gsk.com.ORCID http://orcid.org/0009-0001-4950-8687

Funding

GlaxoSmithKline 207499
6 · The paper itself

Abstract

The phase 3 DREAMM-8 (NCT04484623) trial assessed belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs bortezomib + Pd (PVd) in lenalidomide-exposed patients with relapsed/refractory multiple myeloma (RRMM) and ≥ 1 prior therapy. Here, we present findings from Japanese patients (data cutoff: 27-May-24). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), duration of response (DoR), and safety. Overall, 21 patients were randomized 1:1 to BPd (N = 10) and PVd (N = 11). Median follow-up was 13.8 months (range 0.23-26.71). For BPd vs PVd, median PFS was not reached (NR; 95% CI 0.2-NR) vs 14.8 months (95% CI 1.9-NR; HR 0.53; 95% CI 0.1-2.8); ORR was 90% (9/10) vs 73% (8/11), including very good partial response or better in 70% (7/10) vs 36% (4/11); median DoR was NR vs 17.5 months. The safety profile was consistent with the global cohort. Ocular adverse events were more common with BPd vs PVd (90% [9/10] vs 9% [1/11]) and a majority were transient and reversible. While the sample size of this study is small, findings were aligned with the global cohort. BPd showed favorable efficacy compared with PVd, with a manageable safety profile in lenalidomide-exposed Japanese patients with RRMM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedDexamethasoneEast Asian PeopleFemaleHumansJapanMaleMiddle AgedProgression-Free SurvivalThalidomideTreatment OutcomeAntibodies, Monoclonal, Humanizedbelantamab mafodotinDexamethasonepomalidomideThalidomideB-cell maturation antigenBelantamab mafodotinJapanRelapsed/refractory multiple myeloma

Identifiers

PMID41493718
PMCPMC13171770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.